Literature DB >> 24249730

Protective role of the neuropeptide urocortin II against experimental sepsis and leishmaniasis by direct killing of pathogens.

Jenny Campos-Salinas1, Marta Caro, Antonio Cavazzuti, Irene Forte-Lago, Stephen M Beverley, Francisco O'Valle, Elena Gonzalez-Rey.   

Abstract

We currently face an alarming resurgence in infectious diseases characterized by antimicrobial resistance and therapeutic failure. This has generated the urgent need of developing new therapeutic approaches that include agents with nontraditional modes of action. A recent interest focused on approaches based on our natural immune defenses, especially on peptides that combine innate antimicrobial activity against diverse pathogens and immunoregulatory functions. In this study, to our knowledge, we describe for the first time the antimicrobial activity of the neuropeptide urocortin II (UCNII) against a panel of Gram-positive and Gram-negative bacteria and tropical parasites of the genus Leishmania. Importantly, this cytotoxicity was selective for pathogens, because UCNII did not affect mammalian cell viability. Structurally, UCNII has a cationic and amphipathic design that resembles antimicrobial peptides. Using mutants and UCNII fragments, we determined the structural requirements for the interaction between the peptide and the surface of pathogen. Following its binding to pathogen, UCNII caused cell death through different membrane-disrupting mechanisms that involve aggregation and membrane depolarization in bacteria and pore formation in Leishmania. Noteworthily, UCNII killed the infective form of Leishmania major even inside the infected macrophages. Consequently, UCNII prevented mortality caused by polymicrobial sepsis and ameliorated pathological signs of cutaneous leishmaniasis. Besides its presence in body physical and mucosal barriers, we found that innate immune cells produce UCNII in response to infections. Therefore, UCNII could be considered as an ancient highly-conserved host peptide involved in the natural antimicrobial defense and emerge as an attractive alternative to current treatments for microbial disorders with associated drug resistances.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24249730      PMCID: PMC3953160          DOI: 10.4049/jimmunol.1301921

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  52 in total

1.  Structure-activity relationship study of antimicrobial dermaseptin S4 showing the consequences of peptide oligomerization on selective cytotoxicity.

Authors:  R Feder; A Dagan; A Mor
Journal:  J Biol Chem       Date:  2000-02-11       Impact factor: 5.157

Review 2.  International Union of Pharmacology. XXXVI. Current status of the nomenclature for receptors for corticotropin-releasing factor and their ligands.

Authors:  Richard L Hauger; Dimitri E Grigoriadis; Mary F Dallman; Paul M Plotsky; Wylie W Vale; Frank M Dautzenberg
Journal:  Pharmacol Rev       Date:  2003-03       Impact factor: 25.468

Review 3.  Molecular basis of bacterial outer membrane permeability revisited.

Authors:  Hiroshi Nikaido
Journal:  Microbiol Mol Biol Rev       Date:  2003-12       Impact factor: 11.056

4.  Neuropeptides kill African trypanosomes by targeting intracellular compartments and inducing autophagic-like cell death.

Authors:  M Delgado; P Anderson; J A Garcia-Salcedo; M Caro; E Gonzalez-Rey
Journal:  Cell Death Differ       Date:  2008-12-05       Impact factor: 15.828

Review 5.  Multifunctional host defense peptides: antiparasitic activities.

Authors:  Amram Mor
Journal:  FEBS J       Date:  2009-10-09       Impact factor: 5.542

6.  Urocortin is a novel regulator of osteoclast differentiation and function through inhibition of a canonical transient receptor potential 1-like cation channel.

Authors:  Charlotte E Combs; Karen Fuller; Hashethra Kumar; Anthony P Albert; Grisha Pirianov; James McCormick; Ian C Locke; Timothy J Chambers; Kevin M Lawrence
Journal:  J Endocrinol       Date:  2011-11-14       Impact factor: 4.286

7.  Neuropeptides rescue mice from lethal sepsis by down-regulating secretion of the late-acting inflammatory mediator high mobility group box 1.

Authors:  Alejo Chorny; Mario Delgado
Journal:  Am J Pathol       Date:  2008-04-01       Impact factor: 4.307

8.  Three-amino acid motifs of urocortin II and III determine their CRF receptor subtype selectivity.

Authors:  Olaf Jahn; Hossein Tezval; Lars van Werven; Klaus Eckart; Joachim Spiess
Journal:  Neuropharmacology       Date:  2004-08       Impact factor: 5.250

9.  Characterization of a corticotropin-releasing factor (CRF)/diuretic hormone-like peptide from tunicates: insight into the origins of the vertebrate CRF family.

Authors:  David A Lovejoy; Dalia Barsyte-Lovejoy
Journal:  Gen Comp Endocrinol       Date:  2009-07-29       Impact factor: 2.822

10.  Immune responses associated with susceptibility of C57BL/10 mice to Leishmania amazonensis.

Authors:  L C Afonso; P Scott
Journal:  Infect Immun       Date:  1993-07       Impact factor: 3.441

View more
  3 in total

1.  Reduction toxicity of Amphotericin B through loading into a novel nanoformulation of anionic linear globular dendrimer for improve treatment of leishmania major.

Authors:  Tahereh Zadeh Mehrizi; Mehdi Shafiee Ardestani; Ali Khamesipour; Mostafa Haji Molla Hoseini; Nariman Mosaffa; Ali Anissian; Amitis Ramezani
Journal:  J Mater Sci Mater Med       Date:  2018-07-28       Impact factor: 3.896

Review 2.  Peptides to Tackle Leishmaniasis: Current Status and Future Directions.

Authors:  Alberto A Robles-Loaiza; Edgar A Pinos-Tamayo; Bruno Mendes; Cátia Teixeira; Cláudia Alves; Paula Gomes; José R Almeida
Journal:  Int J Mol Sci       Date:  2021-04-22       Impact factor: 5.923

3.  Novel Nanosized Chitosan-Betulinic Acid Against Resistant Leishmania Major and First Clinical Observation of such parasite in Kidney.

Authors:  Tahereh Zadeh Mehrizi; Mehdi Shafiee Ardestani; Mostafa Haji Molla Hoseini; Ali Khamesipour; Nariman Mosaffa; Amitis Ramezani
Journal:  Sci Rep       Date:  2018-08-06       Impact factor: 4.379

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.